Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This study evaluates generic emtricitabine(FTC) efficacy and safety in Chinese naive pregnant
chronic hepatitis B patients. Single group patients were enrolled to receive emtricitabine
till 48 weeks after delivery.
Phase:
Phase 4
Details
Lead Sponsor:
Asian-Pacific Alliance of Liver Disease, Beijing
Collaborators:
Beijing Ditan Hospital Hebei Medical University Pharmaceutical Factory National Health and Family Planning Commission, P.R.China